Renalytix (Reg S) (RENX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

5.47p
   
  • Change Today:
      0.12p
  • 52 Week High: 8.52
  • 52 Week Low: 1.73
  • Currency: UK Pounds
  • Shares Issued: 561.38m
  • Volume: 843,324
  • Market Cap: £30.69m
  • RiskGrade: 348

RENX Overview

RenalytixAI is a developer of artificial intelligence (AI) enabled clinical decision support solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -1293.5% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 6.6 n/a
Pr/Book n/a  
Latest F'cast
Revenue -32.7% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

RENX Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-20 n/a (10.61) (16.00)¢ n/a n/a n/a n/a 0.0%
30-Jun-21 1.49 (35.79) (43.00)¢ n/a n/a n/a n/a 0.0%
30-Jun-22 2.97 (49.63) (78.00)¢ n/a n/a n/a n/a 0.0%
30-Jun-23 3.40 (45.60) (55.00)p n/a n/a n/a n/a 0.0%
30-Jun-24 2.29 (33.45) (31.00)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

RENX Company Announcements

US Kidney Care National Plan 22-Oct-2026 07:00 RNS
Holding(s) in Company 19-Oct-2026 13:15 RNS
Holding(s) in Company 05-Oct-2026 10:25 RNS

RENX ShareCast News

Holding(s) in Company 24-Dec-2025 ShareCast
Holding(s) in Company 23-Dec-2025 ShareCast
Holding(s) in Company 19-Dec-2025 ShareCast

Latest RENX Director Deals

Traded Action Notifier PriceAmountValue
29-Sep-26 Buy Christopher H B Mills 6.00p 1,166,667 £70,000.02
29-Sep-26 Sell Christopher H B Mills 6.00p 1,166,667 £70,000.02
15-Sep-26 Buy James Renwick McCullough 309.41p 250 £773.52

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

RENX Market Data

Currency UK Pounds
Share Price 5.47p
Change Today 0.12p
% Change 2.18 %
52 Week High 8.52
52 Week Low 1.73
Volume 843,324
Shares Issued 561.38m
Market Cap £30.69m
RiskGrade 348

RENX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
7.7% below the market average7.7% below the market average7.7% below the market average7.7% below the market average7.7% below the market average
40% below the sector average40% below the sector average40% below the sector average40% below the sector average40% below the sector average
Price Trend
95.29% below the market average95.29% below the market average95.29% below the market average95.29% below the market average95.29% below the market average
76.74% below the sector average76.74% below the sector average76.74% below the sector average76.74% below the sector average76.74% below the sector average
Income Not Available
Growth
20.37% below the market average20.37% below the market average20.37% below the market average20.37% below the market average20.37% below the market average
50% below the sector average50% below the sector average50% below the sector average50% below the sector average50% below the sector average

RENX Dividends

No dividends found

Trades for 22-Oct-2026

Time Volume / Share Price
09:19 20,000 @ 5.60p
09:16 2,017 @ 5.30p
09:16 911 @ 5.80p
09:16 980 @ 5.80p
09:16 2,105 @ 5.30p

RENX Key Personnel

CEO James Renwick McCullough

Top of Page